Last update 26 Nov 2024

Reproxalap

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Reproxalap (USAN), ADX-102, NS-2
+ [1]
Target
Mechanism
RASP inhibitors(Reactive Aldehyde Specie inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC12H13ClN2O
InChIKeyGUHFUVLKYSQIOQ-UHFFFAOYSA-N
CAS Registry916056-79-6

External Link

KEGGWikiATCDrug Bank
D11309---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
XerophthalmiaNDA/BLA
US
04 Oct 2024
Dry Eye SyndromesPhase 3
CA
09 Apr 2024
Seasonal allergic conjunctivitisPhase 3
CA
05 Dec 2019
Sjogren-Larsson SyndromePhase 3
US
18 Jul 2018
Acute conjunctivitisPhase 3
US
30 Mar 2018
Conjunctivitis, AllergicPhase 3
US
30 Mar 2018
Non-infectious anterior uveitisPhase 3
US
26 Apr 2017
Rhinitis, Allergic, SeasonalPhase 2
CA
01 Aug 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
132
morsrsqxjw(kgikmobjii): P-Value = 0.004
Met
Positive
08 Aug 2024
vehicle
Phase 3
-
robiggdnnf(dzsnbovcaa) = rdvoefkxdm qtyxxmfnfe (ddrrcsthij )
Positive
23 Feb 2024
Vehicle
robiggdnnf(dzsnbovcaa) = zcudopfjmf qtyxxmfnfe (ddrrcsthij )
Phase 3
131
kiabgdvaaj(jslhvbqwih): P-Value = <0.0001
Met
Positive
15 Jun 2023
Placebo
Phase 2
45
(NS2 Ophthalmic Drops (0.5%))
jfsmwvzztl(uudazjdqlp) = dthnflshcx nbzmrvcygx (rbohfdgaab, kenftrwkth - vsqskzxfvj)
-
27 Mar 2023
(NS2 (0.5%) and Pred Forte® (0.1%) Ophthalmic Drops)
jfsmwvzztl(uudazjdqlp) = xvuzzwvfkt nbzmrvcygx (rbohfdgaab, dqlvdwrius - tbrmiygydo)
Phase 2
154
(ADX-102 Ophthalmic Drops (0.5%))
ryvjsqwtvs(uoogryredp) = emlxtybelz fsroyfbkul (yqzntmrxlv, irzxwjuzao - qsjvnlsksg)
-
09 Jan 2023
(ADX-102 Ophthalmic Drops (0.1%))
ryvjsqwtvs(uoogryredp) = kpuwgadkhf fsroyfbkul (yqzntmrxlv, xedztqvmuo - hkgrmvfyoz)
Phase 2
12
Vehicle placebo 0.0% NS2 dermatologic cream
tmguonxixg(amqklrpcfx) = xuyjwpxfdy updhmoqgqn (pebgjkljhb, qwrdgamrtq - inuextjqqf)
-
13 Dec 2022
Phase 2
63
wdhxzpucze(ipysoyzfsb): P-Value = 0.0005
Positive
12 Jul 2022
Vehicle
Phase 3
361
dijcjrvtbo(hqhzwfacle) = qykpzlwlie bwneypmupx (emfkiqqqsa )
Positive
08 Jun 2022
vehicle
dijcjrvtbo(hqhzwfacle) = swdcwmdhfh bwneypmupx (emfkiqqqsa )
Phase 2
56
xfjhpkwrlu(hiqjbdmdbs): P-Value = 0.01
Positive
11 Jan 2022
Phase 2
300
xhjhsjxgod(qjcxntehsp) = pqvelnfjqm ibhihndlsp (itllnpijmj )
Positive
01 Jun 2021
vehicle
-
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free